LVTX LAVA Therapeutics N.V.

FDA Catalyst Company
3.55
-0.26  -7%
Previous Close 3.81
Open 3.77
52 Week Low 3.22
52 Week High 13.13
Market Cap $91,503,160
Shares 25,775,538
Float 9,455,875
Enterprise Value $-26,137,992
Volume 4,183
Av. Daily Volume 7,257
Live cash est $88,666,444,222
Cash Burn N/A
No. Mths Cash 12
Insiders % 0.2
Total debt to equity 4.35
Earnings Date 01/01/2001
EPS EST. 1.82
EPS PRIOR. 1.82
EPS 1.82
Rev guidance $10,459,000,000

Biotech Analyst Ratings

Analyst Action Rating Now PT Prior PT Now Last Updated
SVB Leerink Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 11/16/2021
SVB Leerink Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 08/17/2021
Jefferies Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 04/19/2021
JP Morgan Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 04/19/2021
SVB Leerink Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 04/19/2021

Latest News

    • LAVA-051 updated interim clinical data from Phase 1/2a clinical trial in patients with relapsed or refractory chronic lymphocytic leukemia and multiple myeloma to be presented at 2022 ASCO Annual Meeting
    • LAVA-1207 Phase 1/2a trial in metastatic castration-resistant prostate cancer dosed the first patients and is on track to report initial data in H2 2022
    • Cash and investments of $124.2 million as of March 31, 2022

    UTRECHT, The Netherlands and PHILADELPHIA, May 17, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers to transform the treatment of cancer, today announced recent corporate highlights…

    View Full Article
  1. UTRECHT, The Netherlands and PHILADELPHIA, May 12, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ:LVTX), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers to transform the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for LAVA-051, the Company's lead product candidate for the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL), multiple myeloma (MM) and acute myeloid leukemia (AML).

    "FDA clearance of our IND application for LAVA-051 marks the second IND for LAVA and enables us to expand patient enrollment into the U.S. for our…

    View Full Article
  2. UTRECHT, The Netherlands and PHILADELPHIA, May 05, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ:LVTX), an immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers to transform the treatment of cancer, today announced that Stephen Hurly, president and chief executive officer of LAVA Therapeutics, will participate in a fireside chat at the UBS Global Healthcare Conference 2022 being held in New York, NY.

    Presentation Details
    Format: Fireside chat
    Date: Monday, May 23, 2022
    Time: 4:15-4:45p.m. ET.

    A live webcast of the fireside chat and a replay of the fireside chat can be accessed under the "Events" tab on the investor relations section of the LAVA Therapeutics website…

    View Full Article
  3. UTRECHT, The Netherlands and PHILADELPHIA, April 27, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), an immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers to transform the treatment of cancer, today announced the Company will present updated interim data from the dose escalation phase of the ongoing Phase 1/2a clinical trial of LAVA-051 in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago and virtually June 3-7, 2022.

    The details of the poster presentation session are as follows:

    Abstract #: 2577
    Abstract Title: 

    View Full Article
    • LAVA-051 shows encouraging initial safety and pharmacodynamic observations; on track for more dose escalation data from Phase 1/2a trial in Q2 2022
    • LAVA-1207 Phase 1/2a trial in mCRPC on track to report initial data in H2 2022
    • New pipeline program: LAVA-1266, a CD123-directed Gammabody™ for hematological malignancies
    • Strong balance sheet with cash and investments of $133.2 million as of December 31, 2021

    UTRECHT, The Netherlands and PHILADELPHIA, March 24, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), an immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers to transform the treatment of cancer, today announced recent corporate highlights and financial results…

    View Full Article
View All LAVA Therapeutics N.V. News